Key Highlights

  • Hemab Therapeutics Holdings (NASDAQ:COAG) traded at USD 44.30 in a published screener snapshot on November 5, 2026, after a 43.77% gain over one month and 13.90% over one week, placing it among the best-performing mid caps.
  • The 1M gain follows a 72.09% rise over six months, yet the stock is down 15.64% over three months, so the one-month surge sits inside a volatile path rather than a straight climb.
  • The IPO priced on April 30, 2026 at USD 18 for 16.8 million shares, upsized from 11.8 million, raising about USD 302 million; the price of USD 44.30 is 146% above it (calculated).
  • The latest session change was negative 1.76%, and no single catalyst was identified for the month, so the move is described below as a mix of pipeline sentiment and general small and Mid cap biotech mechanics.

What Moved Hemab Therapeutics (43.77% in 1M)

The published screener snapshot of November 5, 2026 shows Hemab Therapeutics Holdings at USD 44.30. The one-month gain of 43.77% and the one-week gain of 13.90% put the stock in the mid cap bucket of USD 2 billion to USD 10 billion, among the strongest performers. The latest session fell 1.76%, so part of the run was given back. Over three months the stock is down 15.64%, while the six-month gain is 72.09%; a year-to-date figure was not visible. The shares listed on Nasdaq under COAG after pricing on April 30, 2026 at USD 18, the top of a USD 16 to USD 18 range, with Goldman Sachs, Jefferies and Evercore ISI as joint bookrunners. A published Novo Holdings release put the first day close at nearly 90% above the offer price.

Why a Stock Like Hemab Re-Rates

No single catalyst was identified for the past month, and no earnings, trial readout or filing dated within the window was confirmed. What can be sourced is the pipeline. Sutacimig, formerly HMB-001, is a subcutaneous bispecific antibody for Glanzmann thrombasthenia. The FDA granted it Breakthrough Therapy Designation in March 2026 after a Phase I/II trial, and the IPO documents describe a completed Phase 2 with Phase 3 in Glanzmann thrombasthenia and Phase 2 in Factor VII deficiency ahead. HMB-002 is in Phase 1/2 for von Willebrand disease. As general context, young biotechs often re-rate on analyst initiations after quiet periods end, rotation into small and mid cap healthcare, and low trading float after an IPO. Those are mechanisms, not confirmed causes here.

Valuation, Liquidity and Risks After a 43.77% Run

Hemab has no commercial Revenue in the figures found, so price to sales and P/E are not meaningful, and valuation rests on the pipeline. A 52-week range and average Volume were not confirmed, so none is quoted. A recent IPO can have a modest public float, meaning a small number of trades can move the price and spreads can be wide. The stock is 146% above its USD 18 Offer Price (calculated), so expectations are high. A move of 43.77% in one month can reverse as quickly as it formed, and the 15.64% fall over three months shows that has already happened once. Clinical setbacks, a delay to Phase 3, financing needs and lock-up expirations are the specific risks for a pre-revenue biotech.

Where Things Stand

The jump in Hemab Therapeutics Holdings (NASDAQ:COAG) appears to reflect pipeline momentum and sector rotation rather than a confirmed single catalyst. At USD 44.30, with 43.77% in one month and 13.90% in one week, it ranks among the strongest mid caps in a published screener snapshot of November 5, 2026. The mid cap bucket spans USD 2 billion to USD 10 billion. The 15.64% three-month decline and 1.76% latest-session dip show how uneven the path has been. Nothing here implies the move will continue.